Rabies-Pipeline Review, H1 2017

Rabies-Pipeline Review, H1 2017


  • Products Id :- GMDHC9260IDB
  • |
  • Pages: 72
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rabies-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies-Pipeline Review, H1 2017, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 2, 10, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Rabies-Overview

Rabies-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rabies-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rabies-Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Celltrion Inc

Curevac AG

Humabs BioMed SA

Indian Immunologicals Ltd

Kamada Ltd

Molecular Targeting Technologies Inc

NanoViricides Inc

Novavax Inc

PaxVax Inc

Sanofi Pasteur SA

Synermore Biologics Co Ltd

Trellis Bioscience Inc

VBI Vaccines Inc

Zydus Cadila Healthcare Ltd

Rabies-Drug Profiles

(Ebola [Zaire] + rabies) (bivalent) vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNSP-333S1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTP-19-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-8102-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMT-504-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MAb-3-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Rabies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Glycoprotein for Rabies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Target Glycoprotein for Rabies-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nadorameran-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RabiCide-I-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies [strain Wistar PM/WI 38-1503-3M] vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies immune globulin (human)-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rabies vaccine 1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rabimabs-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RabiVir-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-20-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVC-58-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SO-57-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SOJB-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYN-023-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YSON-001-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rabies-Dormant Projects

Rabies-Product Development Milestones

Featured News & Press Releases

Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference

Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine

Nov 07, 2016: Kedrion Biopharma and Kamada Announce FDA Acceptance of BLA Submission for Human Rabies Immunoglobulin as a Post-Exposure Treatment

Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment

Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant

Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment

Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies

Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies

Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability

Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel

Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America

May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product

Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Rabies, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Rabies, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Rabies-Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017

Rabies-Pipeline by Celltrion Inc, H1 2017

Rabies-Pipeline by Curevac AG, H1 2017

Rabies-Pipeline by Humabs BioMed SA, H1 2017

Rabies-Pipeline by Indian Immunologicals Ltd, H1 2017

Rabies-Pipeline by Kamada Ltd, H1 2017

Rabies-Pipeline by Molecular Targeting Technologies Inc, H1 2017

Rabies-Pipeline by NanoViricides Inc, H1 2017

Rabies-Pipeline by Novavax Inc, H1 2017

Rabies-Pipeline by PaxVax Inc, H1 2017

Rabies-Pipeline by Sanofi Pasteur SA, H1 2017

Rabies-Pipeline by Synermore Biologics Co Ltd, H1 2017

Rabies-Pipeline by Trellis Bioscience Inc, H1 2017

Rabies-Pipeline by VBI Vaccines Inc, H1 2017

Rabies-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Rabies-Dormant Projects, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Beijing Minhai Biotechnology Co Ltd, Celltrion Inc, Curevac AG, Humabs BioMed SA, Indian Immunologicals Ltd, Kamada Ltd, Molecular Targeting Technologies Inc, NanoViricides Inc, Novavax Inc, PaxVax Inc, Sanofi Pasteur SA, Synermore Biologics Co Ltd, Trellis Bioscience Inc, VBI Vaccines Inc, Zydus Cadila Healthcare Ltd

Rabies Therapeutic Products under Development, Key Players in Rabies Therapeutics, Rabies Pipeline Overview, Rabies Pipeline, Rabies Pipeline Assessment

select a license
Single User License
USD 2000 INR 145100
Site License
USD 4000 INR 290200
Corporate User License
USD 6000 INR 435300

NEWSLETTER BY CATEGORY




Testimonials

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com